According to our new market research study on “Cell Therapy Instruments Market to 2027 – Global Analysis and Forecast by Product, Cell Type, Process, and End User” the market is expected to reach US$ 32,477.15 million by 2027 from US$ 12,340.03 million in 2019. The market is estimated to grow with a CAGR of 13.2% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. The key driving growth factors for the market include increasing developments in cell therapy manufacturing and rising number of approvals for cell-based therapies; whereas, high cost of cell therapy production and cell therapy are expected to hinder market growth.
Request for sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00003481/
Based on the product, the cell therapy instruments market is segmented into consumables, equipment, systems, and software. In 2019, the consumables segment accounted for the highest share of the market. The growth of this segment is attributed to the rising research activities that demand reagents, kits, and lab wares in higher quantity. Also, the increased production of cell therapies for commercialization has influenced the market for the consumables segments. Additionally, the rising adoption of cell therapy has increased the demand for storage consumables to supply and distribute it to the desired places.
Thermo Fisher Scientific Inc.; MERCK KGaA; Lonza; Cytiva (GE Healthcare Life Sciences); Terumo Corporation; BD; Miltenyi Biotec; STEMCELL Technologies Inc.; Sartorius AG; and Danaher Corporation (Beckman Coulter Inc.) are among the leading companies operating in the cell therapy instruments market. The companies have adopted inorganic and organic growth strategies to expand their global footprints, and product portfolio to meet the rising demand for the cell therapy products and services. For instance, in March 2019, Thermo Fisher Scientific Inc. acquired Brammer Bio, to expand the capabilities of Thermo Fisher Scientific Inc. to support high-growth in cell therapy market.
Increasing Developments in Cell Therapy Manufacturing
The increasing research activities in cell therapy have led to extraordinary therapeutic developments in cell therapy instruments to efficiently treat genetic disorders and improve immune system. Various market players provide consumables such as reagents kits, enzymes, instruments, equipment, and software to conduct a wide range of cell therapy processes.
The use of equipment is important for the production of cell therapies such as T cells, HSC, NSC, PSC, and MSC. These cell therapy products are derived from human or animals cells and thus require safe conditions from contamination. Thus, the instruments used for cell therapies help preventing contamination and allows scaling up the production. For instance, companies such as Corning Incorporated; Thermo Fisher Scientific Inc.; Hitachi Chemical Advanced Therapeutics Solutions, LLC; Invetech; Miltenyi Biotec; and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy.
The companies operating in the market are continuously engaged in strategic developments to enhance the product portfolio of cell therapy. For instance, in June 2018, Hitachi Chemical Advanced Therapeutics Solutions, LLC and Invetech entered into a collaborative agreement to commercialize the Counter-Flow Centrifugation system (CFC), an automated platform for cell therapy manufacturing.
Similarly, in May 2019, Cytiva (General Electric Company) commercially introduced a chronicle automation software for cell therapy. The chronicle-automated software comprises a unified digital space that monitors all manufacturing operations and supply chain logistics with real-time data acquisition and notifications. Its electronic batch records trace every manufacturing step with automation and eSOPs designed for specific processes to manage deviations and promote adherence to protocol.
In May 2019, Thermo Fisher Scientific Inc. collaborated with Scinogy to develop and commercialize instruments and reagent systems. This partnership aims to provide a manufacturing system to improve cell and gene therapy, manufacturing productivity, and scalability. Such strategic developments made by the companies are likely to provide technically advanced cell therapy instruments in the market.
The report segments global cell therapy instruments market as follows:
By Cell Type
By End User
Purchase Copy of This Report at https://www.theinsightpartners.com/buy/TIPRE00003481/